Conclusion
Despite important advances in the treatment of ALL, HSCT remains the therapy of choice for patients with failed induction in first remission, relapsed, and refractory. Administering Blinatumomab prior to HSCT with the goal of achieving a negative MRD, deep molecular remission provides a favourable prognosis with better leukemia-free survival rates, overall survival, and less toxicity. The highlights are that 100% of the patients went into remission after Blinatumomab infusion and there was no mortality associated. Our results represent an innovation in Mexico for pediatric patients with refractory ALL and a background to generate experience in a medical group.
TABLE 1: Outpatient administration of Blinatumomab Infusion and Hematopoietic Stem Cell Transplantation as Treatment for Patients with Refractory Acute Lymphoblastic features. 2015-2020. Hospital Infantil Teleton Oncologia.